The Control System
How the cell cycle is regulated — checkpoints and molecular switches
Cell division is among the most consequential decisions a cell makes. Dividing at the wrong time, with damaged DNA, or without completing the previous phase accurately can produce mutant daughter cells — and accumulation of mutations is cancer. The cell has evolved an intricate system of checkpoints and surveillance proteins to ensure division only occurs when conditions are exactly right.
The cell cycle is driven by cyclin-dependent kinases (CDKs) — enzymes that phosphorylate target proteins to push the cycle forward. CDKs are constitutively expressed but inactive without their binding partner proteins called cyclins, which oscillate in concentration through the cycle. Different cyclin-CDK complexes control different transitions.
G1 CK
G1 checkpoint — the most critical commitment point
The G1 checkpoint (restriction point) determines whether the cell commits to division. Three conditions assessed: (1) is the cell large enough? (2) is DNA undamaged? (3) are growth factors present? Molecular mechanism: growth factor signaling → cyclin D accumulates → binds CDK4/6 → complex phosphorylates Rb (retinoblastoma protein) → phosphorylated Rb releases E2F transcription factor → E2F activates S phase genes → cell commits to division.
Rb in its active (unphosphorylated) state is the master brake. Active Rb = cell stopped at G1. Cancer almost universally inactivates this brake — through Rb mutation, cyclin D overexpression, CDK4 amplification, or loss of CDK inhibitors (p16/CDKN2A).
Memory trick: Rb = the brakes. Phosphorylated Rb = brakes OFF = cell divides. Cancer removes the brakes — by mutating Rb, amplifying cyclin D, or deleting p16.
G2 CK
G2 checkpoint — is DNA replication complete and accurate?
The G2 checkpoint verifies that DNA replication was completed and no significant DNA damage remains. ATM kinase (activated by double-strand DNA breaks) → phosphorylates Chk2 → phosphorylates Cdc25C phosphatase → Cdc25C degraded → cannot activate CDK1 → cell arrested in G2. If damage cannot be repaired, p53 triggers apoptosis — eliminating the cell before it can divide with a compromised genome.
M CK
M checkpoint — spindle assembly checkpoint
The spindle assembly checkpoint (SAC) occurs at metaphase. It monitors whether all kinetochores are properly attached to spindle microtubules from both poles (biorientation). Mechanism: unattached kinetochores generate the 'wait anaphase' signal (MAD2 inhibits APC/C) → APC/C cannot degrade cyclin B or securin → anaphase blocked. Once all chromosomes are bioriented → MAD2 signal stops → APC/C activated → securin degraded (separase activated, cleaves cohesin, chromatids separate) + cyclin B degraded (CDK1 inactivated, mitosis ends).
Memory trick: SAC = the bouncer at the anaphase door. Every chromosome must show proper attachment before being let through.
Molecular Guardians
p53, Rb, oncogenes, and tumor suppressors
Cell cycle control depends on a balance between proteins driving division (proto-oncogenes) and proteins inhibiting division (tumor suppressors). Cancer disrupts this balance universally — either accelerating the accelerators or removing the brakes.
p53
p53 — guardian of the genome
p53 is normally kept at low levels by MDM2 (an E3 ubiquitin ligase that tags p53 for proteasomal degradation). When DNA damage occurs: ATM/Chk2 phosphorylate p53 → MDM2 cannot bind → p53 accumulates → acts as transcription factor → two programs:
1. Cell cycle arrest: p53 activates p21 → p21 inhibits CDK complexes → G1 (and G2) arrest → time for DNA repair.
2. Apoptosis: if damage is irreparable, p53 activates BAX, PUMA, NOXA → mitochondrial apoptosis → cell death.
p53 is mutated in ~50% of all human cancers — the single most commonly altered gene in cancer. Li-Fraumeni syndrome: inherited germline p53 mutation → >90% lifetime cancer risk.
Memory trick: p53 = the genome's quality inspector. Finds damage → stops the line (arrest) or scraps the product (apoptosis). Lost in half of all cancers.
Onco
Oncogenes — the stuck accelerators
Proto-oncogenes are normal genes that promote growth and division when appropriately activated. Mutations, amplifications, or translocations can convert them to oncogenes — constitutively active drivers of uncontrolled proliferation. Oncogenes act dominantly: one mutant copy is sufficient to promote cancer.
Key oncogenes: RAS (~30% of cancers — KRAS in pancreatic cancer, NRAS in melanoma), MYC (amplified in many cancers → drives proliferative gene expression), HER2 (amplified in ~20% breast cancers → targeted by trastuzumab), BCR-ABL (CML → targeted by imatinib), BRAF V600E (50% of melanomas → targeted by vemurafenib).
Memory trick: Oncogene = gas pedal stuck down. One mutant copy = accelerating forever. Dominant — can't be rescued by the normal copy.
TS
Tumor suppressors — both brakes must fail
Tumor suppressors inhibit division, promote DNA repair, or trigger apoptosis. They act recessively — BOTH copies must be lost or inactivated before protection is removed. This is Knudson's two-hit hypothesis (1971): two independent mutational events ('hits') are required to inactivate a tumor suppressor gene completely.
In hereditary cancer syndromes (BRCA1, RB1, APC): one mutant copy inherited in every cell (hit 1) — one somatic mutation in any cell provides the second hit (hit 2) → tumor. This explains why hereditary cancers appear earlier than sporadic cancers (hit 1 already done at birth).
Key tumor suppressors: RB1 (G1 checkpoint brake), TP53 (genome guardian), APC (Wnt pathway, colorectal cancer), BRCA1/BRCA2 (DNA repair, hereditary breast/ovarian cancer), PTEN (PI3K antagonist), VHL (renal cell carcinoma).
Memory trick: Tumor suppressor = the brakes. Both copies must fail to lose braking. Two hits. Hereditary cancer = born with one hit already done.
🔬 Clinical Scenario — Cell Cycle Control and Cancer Therapy
Understanding checkpoints and their molecular components explains how cancer drugs work:
A
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib). Block CDK4 and CDK6 → Rb remains unphosphorylated → E2F stays inhibited → cells cannot enter S phase → arrested in G1. Used in HR+/HER2- breast cancer combined with hormone therapy. Side effects: bone marrow suppression (rapidly dividing marrow cells also need CDK4/6).
B
PARP inhibitors (olaparib, niraparib) for BRCA-mutant cancers. BRCA1/2 are required for homologous recombination (HR) DNA repair. BRCA-mutant cancer cells cannot repair double-strand DNA breaks by HR. PARP inhibitors block base excision repair (single-strand break repair). With both repair pathways blocked → DNA damage accumulates → genome catastrophe → death. This is synthetic lethality — each defect alone is survivable; together they are lethal.
C
Checkpoint kinase inhibitors (ATR/Chk1 inhibitors). Cancer cells often lose the G1 checkpoint (via p53 mutation) and rely heavily on the G2 checkpoint. ATR/Chk1 inhibitors remove the G2 checkpoint safety net → cells with unrepaired DNA enter mitosis → catastrophic mitotic failure → death. Normal cells with intact G1 checkpoints are relatively spared.
D
MDM2 inhibitors (nutlins, AMG-232). In cancers with wild-type p53 but overexpressed MDM2, blocking MDM2-p53 interaction → p53 accumulates → cell cycle arrest and apoptosis without requiring DNA damage. In clinical trials for liposarcoma (frequently amplifies MDM2) and other wild-type p53 cancers.
📌 Exam Application
Cell cycle control is tested in every cancer biology and cell biology course:
1. Three checkpoints: G1 (Rb/E2F, growth factors, DNA integrity), G2 (ATM/ATR/Chk, replication completeness), M (spindle assembly checkpoint, kinetochore biorientation).
2. Cyclin-CDK logic: CDK levels are CONSTANT. CYCLIN levels oscillate. Cyclin D-CDK4/6 → G1. Cyclin E-CDK2 → S phase. Cyclin B-CDK1 (MPF) → mitosis.
3. p53: DNA damage → p53 accumulates → p21 (arrest) or BAX/PUMA (apoptosis). Mutated in ~50% of cancers. Li-Fraumeni syndrome = inherited p53 mutation.
4. Oncogene (dominant, one hit) vs tumor suppressor (recessive, two hits).
5. Two-hit hypothesis: Knudson. Both copies of tumor suppressor must be lost. Hereditary = born with hit 1.
⚠️ The Most Commonly Missed Cell Cycle Concepts
Cyclin levels fluctuate; CDK levels are constant. CDK is always present but inactive without its cyclin partner. Cyclin concentrations rise and fall at specific cell cycle phases — this is what drives CDK activity up and down. Exam questions often state 'CDK levels oscillate' — this is wrong. Cyclin levels oscillate.
Oncogenes are dominant; tumor suppressors are recessive. One mutant oncogene copy = cancer promotion (the normal copy is irrelevant). Two copies of a tumor suppressor must be lost before cancer protection is removed. This explains the difference between hereditary cancer risk patterns: inheriting one mutant tumor suppressor copy (already at one hit) means only one more somatic mutation needed → earlier, more frequent cancer.
p21 is NOT p53. p53 is the transcription factor activated by DNA damage. p21 (also called CIP1 or WAF1) is a CDK inhibitor whose expression is ACTIVATED BY p53. p53 → p21 → CDK inhibition → G1 arrest. They are separate proteins in a pathway. Some exams try to ask specifically which one does which.
✓ Quick Self-Test
1. What are the three cell cycle checkpoints and what does each monitor?
2. How do cyclins and CDKs work together to control the cell cycle?
3. What does p53 do when DNA damage is detected — and what does it activate?
4. What is the key difference between oncogenes and tumor suppressors in terms of how many mutational events are needed to promote cancer?
5. Explain Knudson's two-hit hypothesis using the retinoblastoma example.
Answers:
1. G1 checkpoint: cell size, DNA integrity, and growth factor presence — commits cell to division. G2 checkpoint: verifies DNA replication was completed accurately and no significant damage remains. M checkpoint (SAC): monitors whether all kinetochores are properly attached to spindle microtubules from both poles before anaphase.
2. CDK levels are constant throughout the cell cycle but CDKs are inactive without their binding partner. Cyclin concentrations rise and fall at specific phases — when a cyclin accumulates it binds its CDK, activating the kinase, which phosphorylates target proteins to drive the cycle forward. When the cyclin is degraded (often by APC/C), the CDK becomes inactive.
3. DNA damage → ATM/Chk2 phosphorylate p53 → MDM2 can no longer bind and degrade p53 → p53 accumulates → activates p21 transcription (p21 inhibits CDK complexes → G1/G2 arrest → time for repair) AND activates pro-apoptotic genes (BAX, PUMA, NOXA) if damage is irreparable → mitochondrial apoptosis.
4. Oncogenes are dominant — one mutant copy is sufficient to promote cancer (the normal copy cannot overcome the constitutively active mutant). Tumor suppressors are recessive — both copies must be lost before cancer protection is removed (Knudson's two-hit hypothesis).
5. RB1 has two copies in every cell. In hereditary retinoblastoma, one mutant RB1 copy is inherited in every retinal cell (hit 1 — already done at birth). A single somatic mutation inactivating the remaining copy in any retinal cell (hit 2) → both copies lost → no Rb braking → uncontrolled retinal cell division → tumor. This explains why hereditary retinoblastoma appears earlier and is often bilateral, while sporadic retinoblastoma (requiring both hits to occur somatically in the same cell) appears later and is usually unilateral.